Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ixekizumab effectively treats generalized pustular psoriasis.

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.

In a post-hoc analysis of six trials, this study observed that both adult and pediatric patients with moderate-to-severe palmoplantar psoriasis treated with ixekizumab experienced rapid and complete clearance of lesions, sustained for up to 5 years in adults and 2 years in children.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.

In this case report, a 28-year-old Chinese man with severe dissecting cellulitis of the scalp experienced nodules resolution and hair regrowth after treatment with ixekizumab and tofacitinib, marking the first reported use of this drug combination for the condition.

In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

This review discusses recent advancements in therapies for ichthyosis, highlighting promising prospects in protein replacement and gene therapy, but it reports no new clinical results.

This review discusses the complexities of managing adolescent psoriasis amidst challenges like identity formation and parent-adolescent dynamics, and proposes updated management strategies for 21st-century adolescents, but reports no new clinical results.

This report discusses two patients with plaque psoriasis who developed hypertrichosis, or excessive hair growth, while undergoing interleukin-17A inhibitor therapy.

This research notes that biologics and small molecules are effective for treating nail psoriasis and alopecia areata, albeit with precautions for adverse events, but no clinical trials have been published for their use in treating nail lichen planus and atopic dermatitis.

This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This review summarizes recent developments in dermatology, including advancements in imaging techniques, biologics, and controversies in treatment, but presents no new clinical findings.

In this study, demodicoses were found to be relatively common among immunocompetent patients, with a notable overlap with papulopustular rosacea.

Lichen planus may be associated with a higher risk of metabolic syndrome.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This article reviews the role of perifollicular regulatory T cells in maintaining hair follicle integrity in the context of hidradenitis suppurativa and calls attention to inflammatory mechanisms without reporting new clinical results.

This review discusses the complex causes and treatment challenges of chronic inflammatory skin diseases, emphasizing the need for biomarkers to predict treatment responses; it reports no new clinical results.

This review discusses the relationship between psoriasis and autoimmunity, focusing on autoimmune co-morbidities, but reports no new research findings.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This study observed that patients with alopecia areata often have comorbidities and experience significant healthcare costs, with treatments like systemic therapies being infrequently used.

This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.